Therapeutic Drug Monitoring and Continuous Infusion of Beta-lactam Antibiotics in Patients With Bacteraemia

Sara Thønnings

Status and phase: Withdrawn; Phase 4

Conditions: Bacteremia

Treatments: Drug: Continuous infusion of beta-lactam antibiotics .; Other: Therapeutic drug monitoring of beta-lactam antibiotics.

Study type: Interventional

Funder types: Other

Identifiers

NCT03108690

2015-768

Details and patient eligibility

About

The study investigates whether Therapeutic Drug Monitoring (TDM) and continuous infusion (CI) of beta-lactam antibiotics optimises target concentrations in patients with bacteraemia.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Have a positive blood culture.
• Undergo treatment with either intravenous penicillin, ampicillin, piperacillin/tazobactam, dicloxacillin, cefuroxime or meropenem.
• Hospitalised at Hvidovre University Hospital.
• Age ≥ 18.
• Able to understand and give informed consent.
• Included in the study within 24 hours after the final positive blood culture answer.

Exclusion criteria

• Positive blood culture is interpreted as contamination.
• The patient dies before the intervention.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Factorial Assignment

Masking: Single Blind

---

0 participants in 2 patient groups

TDM and CI.

Experimental group

Description:

Continuous infusion of beta-lactam antibiotics. Therapeutic drug monitoring of beta-lactam antibiotics.

Treatment:

Other: Therapeutic drug monitoring of beta-lactam antibiotics.

Drug: Continuous infusion of beta-lactam antibiotics .

Control

No Intervention group

Description:

Beta-lactam antibiotics given as intermittent infusion. Samples of serum concentration of beta-lactam will be collected for comparison, but blinded during the study.